• Hyun Min Koh, Chang Lim Hyun, Bo Gun Jang, and Hyun Ju Lee.
• Department of Pathology, Gyeongsang National University Changwon Hospital, Changwon.
• Medicine (Baltimore). 2020 Dec 18; 99 (51): e23837e23837.

BackgroundHepatoma-derived growth factor (HDGF) promotes cancer progression and metastasis by interacting with vascular endothelial growth factor, thereby inducing epithelial-to-mesenchymal transition and angiogenesis. Recent studies have correlated increased HDGF levels with poor prognosis in various malignancies, including lung cancer. This meta-analysis systematically assessed the prognostic significance of HDGF expression in patients with non-small cell lung cancer (NSCLC).MethodsEligible studies were identified by searching literature in PubMed, Embase, Scopus, and the Cochrane library until June 2020. The pooled hazard ratio (HR) or odds ratio (OR) with 95% confidence interval (CI) was determined to assess the relationship between HDGF expression and clinical outcome in patients with NSCLC.ResultsThe pooled HRs between high HDGF expression and clinical outcome were 2.20 (95% CI 1.75-2.76, P < .001) and 2.77 (95% CI 1.79-4.29, P < .001) for overall survival and disease-free survival, respectively. High HDGF expression was significantly correlated with a larger tumor size (OR 1.59, 95% CI 1.02-2.46, P = .040).ConclusionHDGF expression is related to clinical outcome and may be a prognostic marker in patients with NSCLC.Copyright © 2020 the Author(s). Published by Wolters Kluwer Health, Inc.

25 keywords...

hide…